GlassScriptPhysician profile
Irvin J Gastman
NPI 1942263843
$9,144.79
in general payments reported to CMS, 2019-2025
27 companies · $599 in 2025
The $599 reported for 2025 was more than what 82% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
See the full distribution for Public Health & General Preventive Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $714 · 2021: $2,160 · 2022: $1,745 · 2023: $1,360 · 2024: $1,583 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,432 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,431.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,458.10 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,323.79 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.09 | 2020-2024 | Jardiance |
| Esperion Therapeutics, INC. | $661.08 | 2021-2025 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals LP | $640.68 | 2020-2025 | Farxiga, Breztri |
| Pfizer INC. | $623.21 | 2019-2024 | |
| Amgen INC. | $509.84 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $502.33 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $437.29 | 2021-2025 | |
| Abbvie INC. | $394.85 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $363.96 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $358.92 | 2021-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $280.71 | 2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $162.44 | 2023-2024 | Inpefa |
| Bioventus LLC | $139.69 | 2020-2023 | Gelsyn-3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.14 | 2021-2023 | Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $82.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $62.60 | 2021 | |
| Eisai INC. | $52.51 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.64 | 2020-2022 | |
| Allergan, INC. | $36.66 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.06 | 2019-2022 | |
| Orthogenrx INC. | $28.38 | 2020 | |
| Exact Sciences Corporation | $26.03 | 2025 | The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $19.47 | 2021 | |
| Pacira Therapeutics, INC. | $19.08 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irvin Gastman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.